丹参酮ⅡA对冠心病大鼠的影响  

Effects of tanshinone Ⅱ A in rats with coronary heart disease

作　　者：刘静[1] 牛一民 李晓敏[1] 李晨露[1] LIU Jing;NIU Yi-min;LI Xiao-min;LI Chen-lu(Department of Pharmacy,Zhongda Hospital,Southeast University,Nanjing 210000,Jiangsu Province,China)

机构地区：[1]东南大学附属中大医院药剂科,江苏南京210000

出　　处：《中国临床药理学杂志》2020年第22期3717-3720,共4页The Chinese Journal of Clinical Pharmacology

基　　金：江苏省科技项目基础研究计划(自然科学基金)-青年基金资助项目(BK20160704)。

摘　　要：目的研究丹参酮ⅡA(TA)对冠心病(CHD)大鼠模型过氧化物酶体增殖物激活型受体(PPAR)α、血脂紊乱及花生四烯酸(AA)途径的影响。方法将SD大鼠分为空白组、模型组、对照组和实验组,每组12只。空白组、模型组给予等量生理盐水灌胃,实验组给予丹参酮ⅡA 1.5 mg·kg^-1,灌胃,对照组给予1.2 mg·kg^-1普伐他汀,灌胃,连续干预2周。以超声心动图评估大鼠心功能,以全自动生化仪检测血脂水平,以Western blot法测定心肌中蛋白含量。结果干预2周后,空白组、模型组、对照组和实验组左心室舒张末期内径(LVEDD)水平分别为(5.69±0.42),(9.32±0.64),(9.13±0.74)和(7.81±0.62)mm,左心室收缩末期内径(LVESD)水平分别为(2.81±0.38),(7.16±1.03),(6.83±0.82)和(5.99±0.58)mm,左心室射血分数(LVEF)水平分别为(83.74±8.25)%,(42.17±12.85)%,(50.67±6.14)%和(62.36±7.29)%,左心室短轴缩短率(LVFS)分别为(50.87±9.14)%,(20.67±6.25)%,(26.38±5.14)%和(34.92±6.08)%,总胆固醇(TC)水平分别为(1.39±0.42),(2.53±0.36),(1.73±0.38)和(1.97±0.41)mmol·L^-1,三酰甘油(TG)水平分别为(1.06±0.28),(2.93±0.41),(1.32±0.25)和(1.67±0.32)mmol·L^-1,低密度脂蛋白胆固醇(LDL-C)水平分别为(0.73±0.16),(1.23±0.21),(0.91±0.24)和(1.03±0.19)mmol·L^-1,高密度脂蛋白胆固醇(HDL-C)水平分别为(0.92±0.11),(0.42±0.14),(0.78±0.09)和(0.58±0.12)mmol·L^-1,差异均有统计学意义(均P<0.05)。结论丹参酮ⅡA可通过调整血脂紊乱、抑制AA途径炎症激活和激活PPARα通路抑制NF-κB激活等途径发挥治疗冠心病机制。Objective To investigate the effects of tanshinone Ⅱ A(TA) on peroxisome proliferator activated receptor(PPAR) α, dyslipidemia and arachidonic acid(AA) pathway in rats with coronary heart disease(CHD). Methods SD rats were divided into blank group, model group, control group and experimental group, with 12 rats in each group. Blank group and model group were given the same amount of normal saline, experimental group was given TA 1.5 mg·kg^-1, control group was given 1.2 mg·kg^-1 pravastatin, continuous intervention for 2 weeks.The cardiac function was assessed by echocardiography, blood lipid level was measured by automatic biochemical instrument, and protein content in myocardium was determined by Western blot. Results After 2 weeks of intervention, the levels of left ventricular end diastolic diameter(LVEDD) in blank group,model group,control group and experimental group were(5. 69 ± 0. 42),(9. 32 ± 0. 64),(9. 13 ± 0. 74) and(7. 81 ± 0. 62) mm,the levels of left ventricular end systolic diameter(LVESD)were(2. 81 ± 0. 38),(7. 16 ± 1. 03),(6. 83 ± 0. 82) and(5. 99 ± 0. 58) mm,the levels of left ventricular ejection fraction(LVEF) were(83. 74 ± 8. 25) %,(42. 17 ± 12. 85) %,(50. 67 ± 6. 14) % and(62. 36 ± 7. 29) %,the left ventricular fractional shortening(LVFS) levels were(50. 87 ± 9. 14) %,(20. 67 ± 6. 25) %,(26. 38 ± 5. 14) % and(34. 92 ± 6. 08) %,the total cholesterol(TC) levels were(1. 39 ± 0. 42),(2. 53 ± 0. 36),(1. 73 ± 0. 38) and(1. 97 ± 0. 41) mmol·L^-1,the levels of triglyceride(TG) were(1. 06 ± 0. 28),(2. 93 ± 0. 41),(1. 32 ± 0. 25)and(1. 67 ± 0. 32) mmol·L^-1,the levels of low density lipoprotein cholesterol(LDL-C) were(0. 73 ± 0. 16),(1. 23 ± 0. 21),(0. 91 ± 0. 24) and(1. 03 ± 0. 19) mmol mmol·L^-1,the levels of high density lipoprotein cholesterol(HDL-C) were(0. 92 ± 0. 11),(0. 42 ± 0. 14),(0. 78 ± 0. 09) and(0. 58 ± 0. 12) mmol·L^-1,all with significant differences(all P < 0. 05). Conclusion TA can regulate lipid disorders,inhibit inflammation activation in AA

关 键 词：冠状动脉粥样硬化性心脏病 丹参酮ⅡA 过氧化物酶体增殖物激活型受体 花生四烯酸 血脂 

分 类 号：R28[医药卫生—中药学]